Gaps and factors in patient awareness of biomarker test timing and purpose in non-small cell lung cancer (NSCLC): Baseline assessment for implementation of 4R Oncology model.

Authors

null

Nisha Anjali Mohindra

Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Nisha Anjali Mohindra , Julia R. Trosman , Stefanie Houseknecht , Josephine Louella Feliciano , Ruth Lauren Sacks , Joan E. Cain , Benjamin Souter , Wendi Waugh , Jennifer Woodyard , Jeremiah Martin , Laura Schmidt , Cara Chang , Anna Rediske , Sonia Zavala , Thomas William Lycan Jr., Nikki A. Martin , Leigh Boehmer , Elana Plotkin , Ashley Lile , Christine B. Weldon

Organizations

Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Center for Business Models on Healthcare, Glencoe, IL, Johns Hopkins Hospital, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Emory University Hospital, Atlanta, GA, Emory University, Atlanta, GA, Grady Memorial Hospital, Atlanta, GA, SOMC Cancer Center, Portsmouth, OH, SOUTHERN OHIO MEDICAL CENTER, Portsmouth, OH, Southern Ohio Medical Center, Portsmouth, OH, Northwestern Memorial Hospital, Chicago, IL, Northwestern University, Chicago, IL, Wake Forest School of Medicine, Winston-Salem, NC, LUNGevity Foundation, Bethesda, MD, Association of Community Cancer Centers, Rockville, MD, Association of Community Cancer Centers (ACCC), Rockville, MD, Center for Business Models in Healthcare, Glencoe, IL

Research Funding

Other Foundation
Lung Cancer Research Foundation, LUNGevity, Pfizer, Association of Community Cancer Centers

Background: Biomarker testing is necessary for optimal 1st line treatment selection in advanced NSCLC. Patient understanding of timing and purpose of biomarker testing is imperative for patient engagement in care, but is challenging to achieve (Martin Oncol Issues 2022). The 4R Oncology model of patient self-management and timely care delivery has been shown to improve patient knowledge of timing/sequence of care in breast cancer (Trosman JCOOP 2021) but has not been studied in NCLSC in relation to biomarker testing. 4R is being implemented at 5 centers (3 community and 2 academic) in NSCLC. We report baseline assessment of patient awareness of biomarker testing timing and purpose to inform 4R implementation. Methods: Pre-implementation surveys of patients with advanced NSCLC at 5 centers Aug – Dec 2022. Metrics are listed in Table. Results: Survey response rate: 46% (65/142). Respondents were 65% white, 42% high school educated or less, 46% with annual income ≤$30K. While all patients were aware of receiving non-biomarker tests, > 40% were not aware of receiving biomarker testing (Table). About half knew why or how long they needed to wait for results, but only 29% received this information from providers. Of those tested, the majority reported provider discussions of biomarkers or therapy selection and were clear about results or therapy selection. Awareness (eg knowing to wait for results before therapy) was associated with receiving printed NSCLC materials (45% vs 7%, p < .01), education above high school (69% vs 41%, p = .03) and income > $30K (67% vs 32%, p = .01). Willingness to wait for test results was associated with knowing how to prepare for treatment while waiting (89% vs 46%, p < .01). Race did not impact these metrics. Conclusions: Considerable gaps exist in patient awareness of timing and purpose of biomarker testing. We refined the 4R model to emphasize biomarker timing in printed visual material, facilitate patient-provider discussions and engage patients in health maintenance while waiting for results. We revised 4R to a lower literacy level. Results will be reported when available.

% reporting Yes% reporting No% reporting Not sure
Questions asked of all patients, N = 65I received biomarker testing481141
I received other tests (eg imaging) informing my treatment10000
I knew WHY I need to wait for biomarker or other test results to start therapy571231
I knew how long test results will take49843
Providers told me I need to wait for biomarker or other test results to start therapy292843
I was OK waiting for biomarker or other test results before therapy622315
Questions asked of patients who received biomarker test, n = 31Providers discussed biomarker results with me721019
Providers discussed with me how biomarker results impacted my therapy selection741610
Biomarker results were clear to me65269
I was clear WHY my therapy was selected622117

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e21059)

DOI

10.1200/JCO.2023.41.16_suppl.e21059

Abstract #

e21059

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Quality Care Symposium

Awareness of biomarker test timing and purpose in patients with non-small cell lung cancer (NSCLC).

First Author: Nisha Anjali Mohindra

First Author: Julia R. Trosman